The NHS is launching a five-year study to explore the potential of blood tests in diagnosing very early stages of Alzheimer's disease. Detecting the condition at an earlier stage could offer patients more support and provide an opportunity for new treatments to slow its progression.
Currently, there is no single definitive test for Alzheimer's, and diagnosis can take years. Blood tests under development look for traces of brain proteins like tau and amyloid, which accumulate in the brain long before symptoms appear.
Identifying individuals with these markers early could help in administering treatments that clear such protein build-up before cognitive decline sets in.
The study aims to recruit at least 1,000 NHS patients and assess the feasibility and effectiveness of blood-based Alzheimer's biomarkers in real-world settings. Approval from UK regulators and cost-effectiveness considerations will also be crucial for implementing such tests within the NHS.